Positions Available in the Stevens Lab
At this time, there are no Postdoctoral Research Associate positions available in the Stevens Lab. Please do not inquire further with Dr. Stevens.
Prospective graduate students interested in pursuing research in the Department of Pharmaceutical Sciences at Oregon State University should apply through the OSU Graduate School. Please note that direct inquiries to Dr. Stevens regarding admission or funding will not be considered. All applications must be submitted through the official university application process.
Additional Opportunities
The Stevens Lab is pleased to highlight related doctoral opportunities available through the BioTransform Doctoral Network (Marie Skłodowska-Curie Actions – Horizon Europe). These positions are hosted by partner institutions across Europe and focus on the metabolism, bioactivity, and health effects of bilberry and olive bioactives.
For complete details and application instructions, visit the official project website: biotransform-msca.eu.
Open Doctoral Candidate (DC) Positions
DC1 – Tracking differences in gastrointestinal metabolism of bilberry bioactives between healthy/normal weight and prediabetic individuals through the in vitro gastrointestinal simulation model GIDM-colon
Host: University of Antwerp (Belgium)
Application Period: December 1, 2025 – January 31, 2026
Start Date: May 1, 2026
DC2 – Tracking differences in gastrointestinal metabolism of olive oil biophenols between healthy/normal weight and prediabetic/obese individuals through the in vitro gastrointestinal simulation model GIDM-colon
Host: University of Antwerp (Belgium)
Application Period: December 1, 2025 – January 31, 2026
Start Date: May 1, 2026
DC3 – A blinded placebo-controlled human pilot study for the investigation of the role of bilberry and olive bioactives on oxidative stress parameters and inflammatory markers – Relevance in a South-European population
Host: National and Kapodistrian University of Athens / Laiko General Hospital (Greece)
Application Period: October 1 – November 30, 2025
Start Date: March 1, 2026
DC4 – Exploration of metabolism pathways of olive biophenols using UPLC-HRMS/MS profiling and metabolomics approaches
Host: National and Kapodistrian University of Athens (Greece)
Application Period: October 1 – November 30, 2025
Start Date: March 1, 2026
DC5 – A blinded placebo-controlled human pilot study for the investigation of the role of bilberry and olive bioactives on oxidative stress parameters and inflammatory markers – Relevance in a Central-European population
Host: Medical University of Graz (Austria)
Application Period: October 1 – November 30, 2025
Start Date: March 1, 2026
DC6 – Exploration of metabolism pathways and bioactives’ metabolites from bilberries by using UPLC-HRMS approaches
Host: University of Graz (Austria)
Application Period: October 1, 2025 – November 30, 2026
Start Date: March 1, 2026
DC7 – Impact of bilberry and olive bioactives on gut microbiome
Host: Teagasc Food Research Centre (Ireland)
Application Period: December 1, 2025 – January 31, 2026
Start Date: May 1, 2026
DC8 – In vitro microsomal metabolism of dialysates produced in the GIDM-Colon and activity of metabolites
Host: Riga Stradins University (Latvia)
Application Period: December 1, 2025 – January 31, 2026
Start Date: May 1, 2026
DC9 – Exploration of olive and bilberry bioactives bioavalability aspects through advanced in silico techniques
Host: University of Bath (United Kingdom)
Application Period: February 1 – March 31, 2026
Start Date: July 1, 2026
DC10 – Correlation studies between spectrometric, spectroscopic, biochemical, and microbiome sequencing data after intake of bilberry and olive bioactives
Host: Imperial College London (UK)
Application Period: February 1 – March 31, 2026
Start Date: July 1, 2026
DC11 – Synthesis of potentially bioactive metabolites for chemical structure revision, analytical quantification and bioactivity studies
Host: Latvian Institute of Organic Synthesis (Latvia)
Application Period: December 1, 2025 – January 31, 2026
Start Date: May 1 2026
